Scand J Urol Nephrol
-
Scand J Urol Nephrol · Dec 2012
Randomized Controlled Trial Multicenter StudyLong-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Only a few studies with a long-term follow-up exist on patients with carcinoma in situ (CIS) treated with instillation therapy. The objective was to study the long-term outcome of patients with CIS after mitomycin C (MMC) monotherapy or alternating therapy with MMC and bacillus Calmette-Guérin (BCG). ⋯ The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression.
-
Scand J Urol Nephrol · Jan 2006
Multicenter Study Comparative StudyUse of the osmolal gap to guide the start and duration of dialysis in methanol poisoning.
Rapid diagnosis and treatment of methanol poisoning is mandatory. Dependence on serum methanol analysis in this situation may delay diagnosis and treatment. The anion and osmolal gaps have been recommended for use as diagnostic tools, but the use of these gaps to evaluate the length of hemodialysis treatment has only been emphasized in a few reports. We evaluated the usefulness of the osmolal gap in estimating the need for dialysis and the duration of this treatment in 17 methanol-poisoned subjects. ⋯ In the absence of serum methanol analyses, the osmolal gap is useful to assess the indication for and duration of hemodialysis in methanol-poisoned patients. In mass poisoning situations, use of the osmolal gap makes it possible to reduce the duration of dialysis in a safe manner.
-
Scand J Urol Nephrol · Jan 2005
Randomized Controlled Trial Multicenter Study Clinical TrialQuality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
Prostate cancer (PC) is a highly lethal neoplastic disease affecting the physical, mental and social well-being of patients, i.e. their quality of life (QOL). Patients suffering from metastatic PC are faced with serious decisions regarding treatment strategies. Therefore, QOL information has become a crucial element of decision making in this group of patients. The first objective of this study was to describe QOL in a group of patients diagnosed with metastatic PC and skeletal metastases. At the time of evaluation the patients had not received any treatment but were evaluated before entering a study of androgen-modulating therapy (the Scandinavian Prostate Cancer Group study 5). The second objective was to identify demographic and disease-related factors affecting QOL. ⋯ Patients with metastatic PC have reduced QOL. Our findings are in line with those of other studies of QOL among patients with this disease as evaluated by means of the EORTC QLQ-C30 questionnaire. Baseline data from studies like this provide important information when treatment modalities for PC are evaluated.
-
Scand J Urol Nephrol · Apr 1998
Multicenter Study Clinical Trial Controlled Clinical TrialAntiemetic efficacy of prednisolone: a placebo-controlled trial in patients with advanced prostatic cancer treated with estramustine phosphate.
The antiemetic effect of prednisolone on nausea/vomiting was investigated in 67 patients with advanced prostatic cancer and a performance status of < or = 2. The study was a double-blind, placebo-controlled, randomized trial with a parallel group design. The objective was to compare the incidence and severity of nausea/vomiting between the two groups. ⋯ The results indicated that no statistical differences between the two groups of patients were present in AUCs for weeks 1-3 or weeks 1-4. We conclude that it was not possible to demonstrate a significant antiemetic efficacy of prednisolone. However, in all but one case the patients in the prednisolone group could be treated for at least 3 weeks without any major incidents of nausea/vomiting.